Hello,

This letter requests your participation to help us gather more information about your group or company’s COVID-19 testing technology during this critical time in pandemic response worldwide.

For over 200 years, the Mass General Brigham (Partners) healthcare system has been responding to pandemics, global health crises, and changing how medicine is practiced. In response to the unprecedented SARS-CoV-2/COVID-19 pandemic, our world leading medical institutions have formed the Mass General Brigham Center for COVID Innovation. This virtual global community of world leading academic research centers, healthcare systems, biopharmaceutical, device and technology companies is headquartered at Massachusetts General Hospital and Brigham and Women’s Hospital in Boston, Massachusetts. The Center for COVID Innovation has a mandate to find, create, enable, and implement Device, Diagnostic, Data and Therapeutic solutions helping those affected by the pandemic in all its forms.

As part of the Diagnostics Pillar within the MGB Center for COVID Innovation, we have formed the Horizon Technology Initiative to improve COVID testing world-wide by providing a bridge between tech developers and opportunities for clinical use, as well as strategies which will enable the next generation of diagnostic technologies to reach patients rapidly and effectively.

Our strategy involves three activities:

- **Opportunities:** a thorough characterization of unmet clinical needs and opportunities for innovation through market research, canvassing frontline medical practitioners, clinical labs, testing sites, public health officials, gatekeepers, and thought leaders--worldwide;
- **Evaluation:** horizon scanning the pre-commercial landscape to identify and score interesting and potentially powerful technological solutions to unmet clinical needs for SARS-CoV-2/COVID-19 diagnosis and associated testing which can be brought to bear on the current crisis;
- **Engagement:** working together with inventors, technology developers--academic or industrial--to offer market intelligence, COVID testing expertise, access to the CCI Validation Pipeline/Diagnostics Accelerator (founded to provide honest, unbiased testing and evaluation with well-characterized samples), as well commercialization strategies, all geared to aid in the further development of these diagnostics tests and/or technologies and to accelerate their development timeline.

We are contacting you to collect information about your diagnostic technology, which after horizon scanning several hundred diagnostic innovations has come to our attention and made it onto our list of potentially important, impactful products. **If you are interested, we ask you to provide us with further information about your product—you may submit details by completing this survey, you may also find the survey on our website’s homepage (above). If you would like, we are able to sign confidentiality agreements to enable the sharing of information.** The survey is optional but will help us verify the information we’ve already gathered, in addition to opening a line of communication should we mutually agree to engage.

We hope you can join us in this rapidly changing environment of pandemic response by assisting our goal of providing the absolute best technological solutions to meeting the diagnostic clinical needs of COVID-19.

Thank you in advance for your cooperation in this urgent matter, we look forward to the potential of working together,

Wesley P. Wong
Lead, Horizon Technologies Working Group  
MGB Center for COVID Innovation

*Associate Professor of Biological Chemistry & Molecular Pharmacology*  
*Harvard Medical School*  
*Investigator, Program in Cellular and Molecular Medicine*  
*Boston Children’s Hospital*  
*Associate Faculty, Wyss Institute for Bioinspired Engineering*  
*Harvard University*  
*www.wonglab.tch.harvard.edu*

**David R. Walt**  
Co-Director, MGB Center for COVID Innovation  
[https://covidinnovation.partners.org](https://covidinnovation.partners.org)

*Hansjörg Wyss Professor of Biologically Inspired Engineering*  
*Harvard Medical School*  
*Professor of Pathology*  
*Department of Pathology-Brigham and Women’s Hospital*  
*Core Faculty, Wyss Institute for Bioinspired Engineering at Harvard University*  
*HHMI Professor*

Office: 857-307-1112  
dwalt@bwh.harvard.edu  
[http://waltlab.bwh.harvard.edu](http://waltlab.bwh.harvard.edu)  
[https://wyss.harvard.edu/team/core-faculty/david-walt/](https://wyss.harvard.edu/team/core-faculty/david-walt/)  
[brighamandwomens.org](http://www.brighamandwomens.org)